Pemphigus are B-cell-mediated autoimmune diseases affecting skin and mucous membranes. They are characterized by the production of pathogenic autoantibodies directed against desmogleins (Dsg). In this prospective study, we treated 21 pemphigus patients with rituximab and analyzed immunological modifications induced by anti-CD20 immunotherapy. The total depletion of peripheral B cells led to a significant decrease of total serum IgM but not IgG levels. The B-cell depletion was followed by a progressive re-emergence of naive blood B lymphocytes, with one-third of them expressing a transitional CD19 þ CD38 high CD24 high phenotype. In most patients, clinical response to rituximab was closely related to the evolution of anti-Dsg autoantibodies that decreased in patients who achieved complete remission, whereas they remained unchanged or reincreased in relapsing patients. In contrast, serum antimicrobial IgG remained stable after rituximab treatment. B-cell repertoire analysis of three patients using immunoscope showed distortions of VH-IgM and VH-IgG immunoscope profiles before treatment, particularly clonal and oligoclonal expansions in some VH families, which were not found after B-cell reconstitution, following anti-CD20 immunotherapy. The depletion of autoreactive B cells leading to the elimination of anti-Dsg autoantibodies in most remitted patients and the restoration of a diverse B-cell repertoire by naive B lymphocytes may provide an explanation for the long-lasting efficacy of rituximab in pemphigus patients.
INTRODUCTION
Rituximab (Mabthera, Rituxan) is a chimeric IgG1 mAb that targets the CD20 molecule, a transmembrane glycoprotein expressed exclusively in normal and malignant B cells. CD20 expression is regulated during B-cell development in late pre-B cells and extinguished on plasma cells (Riley and Sliwkowski, 2000) . Rituximab is highly effective for in vivo B-cell depletion (Reff et al., 1994) and was originally approved for the treatment of B-cell non-Hodgkin's lymphoma (Cheson, 2002) . It has since become a promising therapeutic approach for other B-cell malignancies. Rituximab may also be used in B-cell-mediated autoimmune diseases by depleting pathogenic or antigen-presenting B cells. Indeed, rituximab has been demonstrated to be effective in the treatment of rheumatoid arthritis (Leandro et al., 2002) , systemic lupus erythematosus (Looney et al., 2005) , dermatomyositis (Levine, 2005) , autoimmune hemolytic anemia (Zecca et al., 2003) , immune thrombocytopenic purpura (Stasi et al., 2001; Giagounidis et al., 2002; Cooper et al., 2004) , acquired hemophilia ), Wegener's granulomatosis (Specks et al., 2001) , and mixed cryoglobulinemia (Sansonno et al., 2003) .
Pemphigus are mucocutaneous autoimmune diseases mediated by IgG autoantibodies directed against keratinocyte adhesion molecules (Martel and Joly, 2001) . Two main classical subtypes of pemphigus have been individualized, pemphigus vulgaris (PV) and pemphigus foliaceus (PF), in which pathogenic autoantibodies are directed against desmosomal transmembrane glycoproteins belonging to the cadherin family, desmoglein 3 (Dsg3), and desmoglein 1 (Dsg1), respectively. Although the autoimmune response in the mucosal form of PV is directed against Dsg3, in the mucocutaneous form of the disease, both Dsg1 and Dsg3 are targeted by autoantibodies (Mahoney et al., 1999; Amagai et al., 1999b) . The autoantibody responses are directed against conformational calcium-dependent epitopes of the Dsg extracellular domain, particularly the N-terminal adhesive region (extracellular 1 and 2 domains) (Sekiguchi et al., 2001) . Anti-Dsg autoantibodies, mainly IgG4 and IgG1, are pathogenic. Their in vivo binding to their targets after transfer into normal mice leads to the loss of adhesion between keratinocytes and the formation of intraepidermal blisters (Roscoe et al., 1985; Amagai et al., 1992 Amagai et al., , 1994 Amagai et al., , 1995 .
Over the past few years, the authors and others have reported the successful treatment of pemphigus patients by anti-CD20 immunotherapy (Ahmed et al., 2006; Cianchini et al., 2007; Joly et al., 2007b) . We have treated pemphigus patients with a simple regimen of one cycle of rituximab in a prospective study, with a 3-year follow-up period. Twentyone patients presenting with PV (n ¼ 14) or PF (n ¼ 7) were included. The outcome of these patients was recently reported (Joly et al., 2007b) . After 3 months, 12 of 14 patients with PV and 6 of 7 with PF experienced complete remission (CR). Nine patients, including 6 patients with PV and 3 with PF relapsed after a mean of 18.9±7.9 months. After a median follow-up of 36 months, 18 patients (86%) were free of disease, including 10 patients with minimal corticosteroid (CS) doses: ''CR on minimal therapy'' of the Consensus Statement (Murrell et al., 2008 ; and 8 patients without steroids treatment: ''CR off therapy'' of the Consensus Statement (Joly et al., 2007a, b) .
To evaluate the effects of rituximab on cellular and humoral immune responses, we determined the number and phenotype of B, T, and NK lymphocytes during the 2-year follow-up period. To analyze the evolution of antibody responses, we determined the following: (i) serum levels of total IgG and IgM; (ii) anti-Dsg1 and anti-Dsg3 autoantibody titers; (iii) serum levels of anti-tetanus toxoid (TT) and antipneumococcal capsular polysaccharide (PCP) antibodies. Finally, using the immunoscope method, we assessed the IgM and IgG B-cell repertoire before treatment and after B-cell reconstitution following rituximab treatment.
RESULTS

Rituximab induced a dramatic depletion of peripheral B cells leading to a drop of serum IgM
Twenty-one days after rituximab treatment, a complete depletion of peripheral B cells was observed in all but two patients, one of whom relapsed on day 120. B-cell depletion lasted between 6 and 12 months after treatment. The total number of CD19 þ cells in peripheral blood decreased significantly, from a median of 298 Â 10 6 l À1 (range 29-752 Â 10 6 l
À1
) at baseline to 0 Â 10 6 l
(range 0-1 Â 10 6 l
) on day 21 (Figure 1a ). The frequency of peripheral blood B cells was similar regardless of anti-CD19, anti-CD20, or anti-CD22 mAbs used. The frequency of peripheral blood B cells decreased significantly, from a median of 11.2% (range 3.3-28.7%) at baseline to 0% (range 0-0.5%) on day 21 (data not shown). Both the total number and the frequency of CD19 þ lymphocytes in peripheral blood remained unchanged between day 21 and month 4. Interestingly, only 10% of patients had recovered their initial total number/frequency of blood B cells 1 year after rituximab infusion. Moreover, 2 years after treatment, median B-cell count remained twofold lower than at baseline (106 Â 10 6 l
vs 298 Â 10 6 l À1 ) ( Figure 1a ). Next, we determined by immunonephelemetry the IgM and IgG levels in patient sera before and after rituximab treatment. Whereas mean serum level of IgG was not modified after rituximab treatment, IgM levels progressively decreased from baseline to day 540 (1.58±1 vs 0.75 ± 0.47 g l À1 ) (Figure 1b) .
Reappearance of peripheral naive and transitional B cells during B-cell reconstitution after rituximab therapy
The phenotype of peripheral blood B cells was compared before and after rituximab treatment ( Figure S1 ). B-cell reconstitution started between month 6 and month 9 ( Figure 1 ) and was mainly composed of B cells with a naive CD19 þ CD27À phenotype (Figure 2a ). In fact, the frequency of CD19 þ CD27À cells increased from a median of 65.2% (range 35.1-95.3%) before treatment to 91.6% (range (a) The horizontal line within each box is the median total number of peripheral blood B cells in pemphigus patients (n ¼ 21). The boxes represent the 25th and 75th percentiles and the whiskers represent the 5th and 95th percentiles of the measured values. The total depletion of peripheral B cells was observed in all but two patients from day 21 to month 6. The B-cell reconstitution in peripheral blood of treated patients started between month 6 and month 9. (b) Total IgG (&) and IgM (') levels were measured in patient sera by immunonephelemetry. Error bar represents standard error of the mean (SEM) (n ¼ 20 for days 0, 180, and 360; n ¼ 9 for days 540 and 720). Concentration of IgM but not IgG was significantly reduced in patient sera after rituximab therapy as compared with baseline. **Po0.01, ***Po0.001.
80.8-99.1%) after B-cell recovery. Interestingly, the frequency of peripheral B cells expressing CD38 high and CD5, both markers of the transitional B-cell stage, increased from a median of 11.9% (range 3.2-24.8%) and 0% (range 0-15.5%) before treatment to 52.5% (range 35.6-78.8%) and 40.6% (range 25.8-98%), respectively, after B-cell recovery (Figure 2b and c). More precisely, approximately 30% of reemerging B cells had a CD19 þ CD38 high CD24
high transitional phenotype (Figure 2d ), which is characteristic of human B-cell emigrants from bone marrow that develop in periphery. It is noteworthy that reappearing B cells slightly overexpressed the CD23 low-affinity IgE receptor (P ¼ 0.018) (data not shown). No significant changes in the frequency of activated B cells (CD19 þ CD86 þ ) were observed between the pre-and post-treatment periods (data not shown).
The frequency of peripheral CD19 þ CD27À, CD19 þ CD5 þ , and CD19 þ CD38 high B-cell subpopulations was then analyzed over a long time duration from the B-cell reconstitution up to 24 months after treatment. Figure 2 shows that the frequency of CD19 þ CD5 þ B cells decreased from 52.5 to 20.2% (P ¼ 0.002), whereas CD19 þ CD27À B cells did not significantly change (P ¼ 0.09). Furthermore, the frequencies of CD19 þ CD38 high and CD19 þ CD38 high CD24
high B cells also decreased from 40.5 and 29.4% to 12.2 and 12.5%, respectively (P ¼ 0.0002 and P ¼ 0.0004) (Figure 2c and d) .
Evolution of the B-cell repertoire after rituximab therapy
The complete VH-IgM and VH-IgG B-cell repertoires were analyzed using the immunoscope method (Lim et al., 2008) , in 3 and 2 rituximab-responder patients, respectively (Table 1) . Among the eight VH families analyzed, only the major ones (VH3a, VH3b, and VH4) are presented (Table 1, Figure 3 ). Before treatment, no difference in the frequency of VH family usage for IgM was detected in PF patient P05. In contrast, PF patient P20 showed an increased frequency of VH4 family usage and proportionally decreased frequencies of VH3a/b usages, as compared with healthy controls. An increased frequency of VH4 usage in the IgG B-cell repertoire was also observed in this patient before treatment. Interestingly, VH3b and VH4 family usages for both IgM and IgG were completely normalized after rituximab treatment, in this patient (Table 1) . Conversely, although the IgM-and IgG-VH family usages in B cells from PV patient P21 were similar to those found in controls, VH3b usage for IgM was decreased and VH3a/b usages for IgG were increased in this patient, after rituximab treatment (Table 1) . Figure 3 shows the diversity of the BCR repertoire through the visualization of the complementarity determining region 3 (CDR3) length distribution for each VH-Cm or VH-Cg rearrangement. For the IgM B-cell repertoire, a polyclonal distribution of the CDR3 with, however, some expanded CDR3 peaks was observed in 2 out of 3 patients before rituximab treatment (that is, VH3b in P5 and P20, VH3a in P20). Interestingly, the increased VH4 usage in P20 was associated with a major clonal expansion ( Figure 3a and Table 1 ). Although the IgM-expressing B cells from P21 had a normal CDR3 length distribution before treatment, IgG immunoscope profiles showed expansion peaks in all VH families (Figure 3b) . Furthermore, the same major expansions detected in VH3b-and VH4-IgM þ B cells of P20 were observed in the IgG þ B cells. Sequence analysis of these CDR3 bands demonstrated the presence of highly recurrent sequences, suggesting the existence of three major B-cell clones in the blood from P20 before rituximab (Table 2) . Following rituximab therapy, all the expansions detected in the IgM and IgG B-cell repertoires were no longer detected, and the immunoscope profiles were typically Gaussian for all VH families. These data indicated that the reconstitution of B lymphocytes following anti-CD20 immunotherapy was associated with the restoration of the BCR repertoire diversity in remitted patients, with a distribution of the CDR3 length that was identical to the one found in blood B cells from healthy controls ( Figure 3 ) and in blood cord B cells (data not shown).
Rituximab induced a decrease of anti-Dsg autoantibodies, but did not affect the production of antimicrobial antibodies Autoantibody responses in pemphigus patients treated by rituximab were evaluated using recombinant Dsg1 and Dsg3 ELISA assays. First, a dramatic decrease of anti-Dsg1 and antiDsg3 IgG antibodies was observed after rituximab treatment in 5 of 6 PF (83%) and in 8 of 12 PV (75%) patients who achieved CR, respectively ( Figure 4a ). Persistent high Dsg1 ELISA values were detected in the one PF patient with treatment failure, and in another PF patient who achieved CR after rituximab treatment but relapsed early in the evolution at day 180. Persistent high titers of anti-Dsg3 antibodies were detected in the two PV patients in partial remission and in two PV patients who achieved clinical remission. During the evolution, high titers of anti-Dsg3 and anti-Dsg1 antibodies were detected in three and four patients with mucosal and cutaneous relapse, respectively ( Figure 4b) . Surprisingly, 5 out of 12 (41.7%) PV patients had persistent high titers or a reincrease of anti-Dsg3 antibodies, while still being in CR ( Figure 4a ).
To disentangle this discrepancy, we first analyzed the evolution of anti-Dsg3 IgG subclasses from PV patients with persistent high titers of anti-Dsg3 antibodies. Before treatment, anti-Dsg3 IgG4 antibodies were predominantly found ( Figure 4c ). Anti-Dsg3 IgG4 antibodies were also detected in serum from PV patients, with mucosal relapses. Surprisingly, anti Dsg3 IgG4 antibodies were also evidenced in the serum from PV patients with ongoing clinical remission, up to 1 year after rituximab treatment, when B cells had remerged ( Figure 4c ). The sera that failed to decline Dsg3 ELISA values despite ongoing clinical remission of mucosal lesions were retested using higher dilutions. After determination of the optimal dilution, a decrease of 56 and 57% of Dsg3 ELISA values was observed during the first year after rituximab treatment in two out of the five highly diluted sera tested, whereas ELISA values of the three other sera remained stable overtime. Interestingly, Dsg3 ELISA values of the two sera that initially declined, progressively reincreased during the second year of follow-up, up to 78 and 153% of baseline values ( Figure S2 ).
In contrast to the marked changes of anti-Dsg antibody titers in patients treated by rituximab, serum levels of antimicrobial antibodies, that is, anti-PCP and anti-TT antibodies, were not significantly modified after treatment (Figure 4d ). Evaluations were validated at the time point (*) when the B-cell repertoire analyses were performed (CR: complete remission).
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Values correspond to the means of body surface area involved. Values were determined by ELISA assays and are expressed in units per milliter of sera (U ml
The mean frequency of VH utilization (compared to all 7 VH families) was determined by quantitative real-time PCR analysis for B cells from patients before (day 0) and after rituximab (*).
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Control values correspond to the mean percentages of VH utilizations obtained from four different healthy donors.
The absolute numbers of peripheral blood CD3 þ T cells, CD4 þ T cells, and NK cells did not vary significantly from baseline to day 21 and remained unchanged during 1 year after the B-cell depletion therapy ( Figure S3a ). In addition, no significant differences were detected in the different blood T-cell subpopulations after treatment ( Figure S3b ). Next, we analyzed whether rituximab therapy could modify the pattern of cytokines produced by T cells. The frequencies of CD4 þ and CD8 þ T-cells producing interferon-g, IL-2, and tumor necrosis factor-a did not change significantly from baseline to months 2, 6, and 12 after rituximab treatment ( Figure S3c ).
DISCUSSION
In this study, we extended the clinical observation of pemphigus patients treated with rituximab (Joly et al., 2007a, b) , by analyzing immunological modifications induced by anti-CD20 immunotherapy in PV and PF patients. Rituximab induced a profound depletion of peripheral blood B cells that lasted at least 6 months in most patients. Interestingly, the median number of B cells remained below the baseline count up to 1-2 years after treatment. Significantly, this B-cell kinetic was very similar to that described previously in patients with B-cell lymphoma (Piro et al., 1999; Anolik et al., 2007) or other B-cell-mediated autoimmune diseases treated with rituximab (Roll et al., 2006) . The B-cell depletion Figure 3 . Effect of rituximab on the B-cell repertoire of pemphigus patients. (a) IgM and (b) IgG B-cell repertoires were studied in pemphigus patients before and after rituximab using the immunoscope method as detailed in Materials and Methods. Peripheral blood mononuclear cells from three pemphigus patients (P05, P20, and P21) were obtained before rituximab treatment and during CR period (day 240, 500, and 600, respectively). Patient characteristics are described in Table 1 . IgG immunoscope analysis was undertaken only for two patients, 1 PV and 1 PF (P20 and P21, respectively). Peripheral blood mononuclear cells from four healthy donors used as control for normal B-cell repertoire were also subjected to immunoscope profiling for IgM and IgG.
Representative VH B-cell profiles are shown for one healthy control. The x axis of immunoscope profiles (spectratypes) indicates CDR3 length, wheeras the y axis displays arbitrary fluorescence intensity of the run-off products. Distortions of the immunoscope profile or contracted spectratypes consisting of 1-4 peaks suggesting the presence of B-cell expansions in patients with active disease are indicated by the arrows. Several immunoscope anomalies (expanded peaks or oligoclonal patterns) turn off to polyclonal profiles in remitted patients after the B-cell depletion therapy.
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induced by rituximab in pemphigus patients led to a significant decrease of the total IgM but not IgG serum levels, as reported previously in patients with lymphoma (McLaughlin et al., 1998) , rheumatoid arthritis (Cambridge et al., 2003) , or systemic lupus erythematosus (Vallerskog et al., 2007) treated with rituximab. This rapid decrease is in accordance with the short half-life of IgM. It might be explained, by the disappearance of IgM-expressing mature B cells, which are known to express CD20. As both short-and long-lived plasma cells do not express CD20 (Radbruch et al., 2006) , Vallerskog et al. (2007) proposed that IgM could be produced by plasmablasts or short-lived plama cells, whereas most IgG-secreting plasma cells are long-lived, explaining the absence of medication of whole IgG level after rituximab treatment.
The reappearance of naive B cells (92%) with an increased expression of CD5 and CD38 high , which are both expressed in transitional B cells, has been described previously during the B-cell repopulation phase in rheumatoid arthritis patients treated by rituximab . It suggests that the re-emergence of peripheral B cells is due to the production of immature B cells in the bone marrow. Indeed, as shown previously in patients with other autoimmune diseases or lymphoma treated by rituximab Roll et al., 2006; Anolik et al., 2007; Sutter et al., 2008) , a high frequency of reappearing B cells from pemphigus patients overexpressed both the CD38 and CD24 molecules, a phenotype that has recently been shown to identify transitional B cells (CD19 þ CD38 To detect potential abnormalities in IgM-and IgGexpressing B cells from patients with active disease, which could be reverted after rituximab therapy, we used an original immunoscope method to study the B-cell repertoire. Before treatment, VH B-cell repertoire analysis showed both oligoclonal and clonal expansions of immunoscope profiles, that is, for P05 and P20 in IgM (2/3 patients) and, for P20 and P21 in IgG (2/2 patients). Strikingly, the major expansions observed in VH-IgM profiles were also detected in VH families of IgG þ B cells of P20. Thus, the three major clones detected in the expanded B-cell populations may reflect antigen-driven clonal B-cell expansions. Interestingly, recent studies showed that anti-Dsg1/3 autoantibodies are genetically characterized by restricted patterns of Ig gene usage and antigen-induced somatic hypermutations (Payne et al., 2005; Qian et al., 2007) . Nevertheless, analysis of the CDR3 sequences of predominant blood B-cell clones from PF patient P20 did not show any identity/homology with those described for anti-Dsg1 antibodies (Payne et al., 2005) . Following rituximab therapy, these expansions were no longer detected and immunoscope profiles were typically Gaussian for all VH families, indicating that the B-cell reconstitution was associated with the restoration of a diverse BCR repertoire in remitted patients. Thus, our results indicated that rituximab treatment abrogates clonal and Table 2 . Analysis of the B-cell clonal expansions in a patient with active PF (P20) 1 The purified CDR3 bands (11 aa or 12 aa) corresponding to expanded peaks were subjected to exhaustive sequencing as previously described (Lim et al, 2008) . 2 Frequencies of redundant aminoacid sequences and clone sequences were estimated among those contained in the same CRD3 peak or Ig isotype.
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VH3b oligoclonal expansions observed in pemphigus patients during active phase of the disease and thus, led to the emergence of a new repertoire in remitted patients. This may account for the long-lasting remissions observed in some patients after only one cycle of rituximab (Joly et al., 2007a, b) . Although serum levels of total IgG were unchanged, we examined the effect of rituximab treatment on anti-Dsg IgG autoantibody response. Clinical response to rituximab was closely related to the evolution of anti-Dsg1 antibodies that dramatically decreased in all patients who achieved CR, whereas they remained unchanged or reincreased after treatment in relapsing patients. On the other hand, persistent high titers of anti-Dsg3 antibodies were observed in 5 of 12 PV patients (41.7%) who maintained a CR as described previously (Arin et al., 2005) . Additional experiments using highly diluted sera confirmed that these sera contained high titers of anti-Dsg3 antibodies, as a transient decrease of Dsg3 antibodies followed by a reincrease of Dsg3 ELISA values was observed in two out of these five sera, whereas Dsg3 ELISA values of the three other sera remained stable overtime. Although discrepancies between the ELISA score and the disease severity have been occasionally reported (Harman et al., 2001; Ishii et al., 2005) , in most cases, a close correlation between ELISA anti-Dsg1/3 antibody titers and disease activity has been reported in PV patients (Ishii et al., 1997; Amagai et al., 1999a; Cheng et al., 2002) . Thus, as pathogenic anti-Dsg1/3 autoantibodies usually belong to the IgG4 subclass, we then analyzed the serum IgG-subclasses from the PV patients in CR with persistent high levels of anti-Dsg3 IgG antibodies. Surprisingly, no modification of anti-Dsg3 IgG-subclasses was evidenced after rituximab treatment, as anti-Dsg3 IgG4 antibodies were detected both in patients with active disease and in those in CR. Therefore, a switch from IgG4 to a non-pathogenic IgG subclass did not account for the discrepancy observed between clinical response and the persistence of anti-Dsg3 antibodies in some patients. On the other hand, compelling evidences tend to demonstrate that epitopes bound by anti-Dsg autoantibodies determine their pathogenic activities and disease activity in pemphigus patients (Sekiguchi et al., 2001; Li et al., 2003; Tsunoda et al., 2003) . We demonstrated in our initial report that sera from PV patients in CR after rituximab, with persistent high levels of anti-Dsg3 antibodies, no longer recognized the pathogenic epitopes that were targeted during active phase of the disease (Joly et al., 2007a, b) . Such a phenomenon has been described previously in endemic PF (Li et al., 2003) . In contrast to the dramatic decrease of anti-Dsg antibody titers observed in most patients having obtained CR, serum levels of anti-TT and anti-PCP antibodies remained stable following rituximab therapy, which may account for the low number of severe infections reported in these patients. Similar observations have been reported previously in rheumatoid arthritis patients treated with rituximab. Indeed, titers of IgM rheumatoid factor and anti-citrullinated peptide autoantibodies was significantly reduced with rituximab, whereas those of anti-PCP and anti-TT antibodies remained unchanged (Cambridge et al., 2003 De Vita et al., 2002) . Similarly, B-cell depletion in systemic lupus erythematosus patients led to a decrease of anti-nucleosome and antidsDNA antibodies, whereas anti-TT and anti-PCP antibody levels did not change significantly after rituximab treatment . The persistence of protective antibodies induced by vaccine or infection after rituximab therapy suggests that these antibody populations may be secreted by long-lived plasma cells. Autoantibodies, in turn, can be secreted by both long-lived and short-lived plasma cells. The development of these later cells can be stopped by anti-CD20 immunotherapy, which induces a B-cell depletion (Odendahl et al., 2000) . Indeed, the existence of long-lived autoreactive plasma cells has been demonstrated in the murine NZB/W model of human systemic lupus erythematosus (Hoyer et al., 2004) . In these mice, both short-and longlived autoreactive plasma cells, constantly generated de novo and contributed to the maintenance of autoantibody level, that is, anti-dsDNA antibodies. The presence of long-life autoantibody-secreting plasma cells might explain the persistence of anti-Dsg antibodies in some patient sera. In transgenic mice expressing human CD20, which was used to mimic B-cell depletion observed in humans, the presence of some factors, that is, B-cell-activating factor belonging to the tumor necrosis factor family (BAFF)/Blys, contributes to the resistance of splenic marginal zone and germinal center B cells to rituximab (Gong et al., 2005) . Thus, the different susceptibility of autoreactive B cells to rituximab may also be explained by their microanatomic location.
Numerous studies have reported modifications of the frequencies of several T-cell subsets in patients with autoimmune diseases after rituximab therapy (Cross et al., 2006; Stasi et al., 2007; Vallerskog et al., 2007) . Although autoreactive B cells require cooperation with Dsg-reactive T cells to produce anti-Dsg autoantibodies in pemphigus , we demonstrated that the frequencies of T-cell subpopulations in patient blood were not affected by the B-cell depletion. However, one should note that we did not focus on changes in the number and phenotype of regulatory or Dsg3-specific autoreactive T cells. Eming et al. (2006) have observed a significant reduction of Dsg3-specific T cells secreting interferon-g in some pemphigus patients following rituximab therapy.
Overall, this study demonstrates that therapeutic effect of rituximab therapy in patients with pemphigus involves the following: (i) the elimination of autoreactive B cells, which in turn leads to a reduction of anti-Dsg antibodies in a majority of patients; (ii) the reappearance of naive B cells characterized by a normal repertoire, which may explain the long-term recovery observed in a part of patients.
MATERIALS AND METHODS
Patients and treatment
Patients with severe PV or PF who fulfilled the classical clinical, histological, and immunological diagnostic criteria (Lever, 1979) were eligible for inclusion if the following criteria were met: (i) lack of response to an 8-week treatment with prednisone 1.5 mg kg À1 day À1 (recalcitrant cases); (ii) occurrence of at least two relapses during the decrease of CS doses despite a minimal prednisone dose of 20 mg day À1 (CS-dependent cases); or (iii) contraindication to CS due to severe associated medical conditions (contraindication to CS (Joly et al., 2007b) . Patients were treated with one cycle of four weekly infusions of rituximab at a dosage of 375 mg m À2 of body surface area on days 1, 8, 15, and 22. CS doses were maintained at the initial dose until patients were clinically free of disease; CS doses were then gradually reduced by 10% twice a month, except for patients with contraindication to CS who were treated with rituximab alone. CR of disease was defined according to the Consensus Statement on Definition of Disease Endpoints and Therapeutic Response for Pemphigus (Murrell et al., 2008) as ''the absence of new or established lesions'', and the healing of all skin and mucosal lesions with complete epithelialization ''CR off therapy'' means that patients were off all systemic therapy. ''CR on therapy'' means that patients were still receiving minimal therapy. Relapse was defined as the occurrence of new cutaneous blisters or oral erosions during treatment. Other therapy that might affect the activity of pemphigus such as intravenous infusions of immune globulin, dapsone, or immunosuppressive drugs was avoided throughout the study period.
Follow-up measurements
Patients were evaluated both clinically and biologically every month during the first year of follow-up and every other month during the second year. The primary end point was the rate of ''complete remission therapy'' 3 months after the last infusion of rituximab.
Flow cytometry analysis
The following fluorochrome-labeled mAbs were obtained from commercial sources: anti-CD3, anti-CD4, anti-CD19, anti-CD20, anti-CD21, anti-CD22, anti-CD23, anti-CD5, anti-CD27, anti-CD38, anti-CD24, anti-CD56, anti-CD86, anti-CD25, anti-CD26, antiCD28, anti-CD38, anti-CD45RA, anti-CD45RO, anti-CD71, anti-DR (Beckman Coulter, Miami, FL); anti-CD27, anti-CD70, anti-CD134 (BD Biosciences Pharmingen, San Diego, CA); anti-CD69 (Becton Dickinson, Franklin Lakes, NJ). Heparinized peripheral blood samples were obtained from pemphigus patients and stained for B, T lymphocytes, and NK cells using matched combinations of fluorescein isothiocyanate (FITC)-, phycoerythrin-, or phycoerythrin-Cy5-conjugated anti-human mAbs. Cell labeling was performed by mixing 100 ml of whole blood with each specific combination of mAbs and maintained for 20 minutes at room temperature in the dark. Red cells were lysed using TQ-prep system (Beckman Coulter). The samples were washed in phosphate-buffered saline for 5 minutes, centrifuged at 2,000 r.p.m. for 5 minutes, and resuspended in 500 ml of phosphate-buffered saline. Flow cytometry analysis was performed on Epics Elite flow cytometer (Beckman Coulter). Lymphocytes were gated according to forward-scatter/sidescatter parameters and fluorescence intensity data were collected on 10 4 -gated lymphocytes. Appropriate conjugated isotype-matched mAbs were used as controls (Beckman Coulter) and stained less than 5% of the cell population.
Intracellular detection of cytokines was performed in peripheral blood mononuclear cells activated with 25 ng ml À1 of phorbol 12-myristate 13-acetate, 1 mg ml À1 of ionomycin and 10 mg ml À1 of Brefeldin-A (Sigma, Saint Louis, MO). Cells were then fixed and permeabilized using the IntraPrep reagents (Immunotech, Marseille, France) according to the manufacturer's instructions. Cells were incubated with phycoerythrin-coupled anti-IL-2, anti-tumor necrosis factor-a (BD Biosciences Pharmingen), or anti-interferon-g (Beckman Coulter) mAbs and analyzed by Epics Elite flow cytometer (Beckman Coulter).
Serum concentrations of IgM and IgG
Serum concentrations of IgM and IgG were determined by immunonephelemetry using BN Prospec II system (Dade Berhing, Deerfield, IL) according to the manufacturer's instructions.
Dsg-specific ELISA assay
To determine anti-Dsg1 and anti-Dsg3 antibody titers, Dsg1-and Dsg3-ELISA tests (MESACUP Desmoglein test, Medical and Biological Laboratories, Nagano, Japan) were performed with 1:100-diluted pemphigus sera according to the manufacturer's instructions. Data are expressed as units per milliter of sera (U ml À1 ). Anti-Dsg1
and anti-Dsg3 values superior to 20 and 14 U ml À1 , respectively, were considered as positive. Optimal serum dilutions for PV patients who achieved CR with high anti-Dsg3 Ab titers were determined before treatment using serially diluted sera from 1:100 to 1:2,000. The optimized index values were calculated by multiplying the obtained index values by the dilution factor (Cheng et al., 2002) . For IgG-subclass determination, the plates were alternatively incubated with 5,000-fold-diluted mouse monoclonal anti-human IgG1, IgG2, IgG3, or IgG4 antibody (Sigma) for 1 hour at room temperature. After washing, the plates were incubated with peroxydase-conjugated goat anti-mouse IgG (1:100,000) (Rockland, Gilbertsville, PA) for 30 minutes and color development was achieved following the manufacturer's instructions.
Serum levels of antimicrobial antibodies
Serum levels of IgG anti-TT and anti-PCP antibodies were determined by ELISA as described previously (Ballet et al., 1987) .
Analysis of BCR repertoire
Total RNA was prepared from peripheral blood mononuclear cells using the RNeasy kit (Sigma, Deisenhofen, Germany). RNA was converted into cDNA following standard protocols by using Superscript II (Invitrogen, Carlsbad, CA, USA), oligo dT primers (Eurogentech, Paris, France), and RNAsin (Invitrogen). PCR reactions were carried out by combining a primer and a specific fluorophorelabeled probe for the constant region CHm with one of eight primers covering the different VH1-7 genes. Reactions were carried out using the Taqman 7300 (Applied Biosystems, Foster City, CA) and standard reagents from Applied Biosystems. Details of the primers and the calculation of the relative transcriptions are filed as European and US patent (Repertoire determination of a lymphocyte B population, WO 2005/059176 A1) and can be obtained through the Pasteur Institute, Paris, France (Lim et al., 2008) . PCR products were then subjected to run-off reactions with a nested fluorescent primer specific for the constant region gene. The fluorescent products were separated and analyzed on an ABI-PRISM 3730 DNA analyzer. The size and intensity of each band were analyzed with Immunoscope software (Pannetier et al., 1993) . Fluorescence intensity of each band was plotted in arbitrary units on the y axis, whereas the x axis corresponds to the CDR3 length in amino acids. Amplification products (bands with CDR3 lengths of 11 and 12 aminoacids in the VH3b and VH4 family, respectively) corresponding to the clonal expansions observed in P20 immunoscope profiles were cloned, sequenced, and analyzed according to the procedure described previously (Lim et al., 2008) .
Statistical analysis
All analyses were performed with Wilcoxon's matched pairs signed rank test and Kruskal-Wallis test except for the comparison of CD38 high CD24
high B-cell frequencies, which were analyzed with the Mann-Whitney test. P-values o0.05 were considered statistically significant.
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SUPPLEMENTARY MATERIAL Figure S1 . Flow cytometry analysis of B-cell phenotype in pemphigus patients treated by rituximab. Figure S2 . Evolution of anti-Dsg3 autoantibodies in PV patients ongoing CR. 
Immunological Effects of Rituximab in Pemphigus
